

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

OVCA429

RRID:CVCL_3936

Type: Cell Line

Proper Citation

RRID:CVCL_3936

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3936

Proper Citation: RRID:CVCL_3936

Description: Cell line OVCA429 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian cystadenocarcinoma

Defining Citation: [PMID:1536252](#), [PMID:6346879](#), [PMID:7028788](#), [PMID:10318951](#), [PMID:10972993](#), [PMID:12080474](#), [PMID:12960427](#), [PMID:16380993](#), [PMID:16382445](#), [PMID:19926575](#), [PMID:20204287](#), [PMID:20596667](#), [PMID:22710073](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:30485824](#)

Comments: Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVCA429

Synonyms: OVCA 429, OvCA 429, OVCA-429, OVCAR-429, OVCAR 429, OVCAR429, OV429

Cross References: BTO:BTO_0002564, EFO:EFO_0006721, ArrayExpress:E-MTAB-2706, BioSample:SAMN03470937, cancercellines:CVCL_3936, Cosmic:924146, Cosmic:927567, Cosmic:1223315, Cosmic:1328064, Cosmic:1434898, Cosmic:2074245, EGA:EGAS00001000610, GEO:GSM95439, GEO:GSM659391, GEO:GSM711704, GEO:GSM851929, IARC_TP53:28487, Pharmacodb:OvCA429_1214_2019, Progenetix:CVCL_3936, Wikidata:Q54936983

ID: CVCL_3936

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260904T015342+0000

Ratings and Alerts

No rating or validation information has been found for OVCA429.

No alerts have been found for OVCA429.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tan GYT, et al. (2026) BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). EMBO molecular medicine, 18(5), 1933.

Han GH, et al. (2026) Clinical and Functional Characterization of PDE1A as a Wnt/?-Catenin-Linked Biomarker of Progression and Platinum Resistance in Epithelial Ovarian Cancer. Oncology research, 34(3), 16.

Wang S, et al. (2025) EMSY enhances glycolysis in ovarian cancer cells. European journal of medical research, 30(1), 890.

Bitler BG, et al. (2025) Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer. Scientific reports, 15(1), 39257.

Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer research, 85(18), 3471.

Sottnik JL, et al. (2024) WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. Cancer research communications, 4(1), 134.

Villagomez FR, et al. (2024) Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents. bioRxiv : the preprint server for biology.

Villagomez FR, et al. (2024) Claudin-4 stabilizes the genome via nuclear and cell cycle remodeling to support ovarian cancer cell survival. Cancer research communications.

Villagomez FR, et al. (2024) Claudin-4 modulates autophagy via SLC1A5/LAT1 as a tolerance mechanism for genomic instability in ovarian cancer. bioRxiv : the preprint server for biology.

Zhou W, et al. (2023) Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer cell, 41(4), 740.

Yamamoto TM, et al. (2022) Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Molecular cancer therapeutics, 21(4), 647.

Zundell JA, et al. (2021) Targeting the IRE1 α /XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers. Cancer research, 81(20), 5325.